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Abstract
• Glioma are brain tumors with very poor prognosis. The standard of
care is surgery followed by radio- and chemo/immuno-therapy, or
combinations thereof, however, healthy cells are affected as well as
tumorous cells and all patients eventually die. Thus, there is a need
to test if recently approved drugs can inhibit the growth and
progression of this tumor. We have developed a Drosophila glioma
model based on the two genetic/ oncogenic pathways known to be
most frequently activated in patients viz., the Ras/MAPK pathway
and the PI3K pathway. We designed a chemical screen involving
drugs targeting Tyrosine kinases (Selleck Biochem Chemical
library) – key enzymes that are activated by oncogenic pathways.
The chemical screen involves feeding glioma containing larvae
10uM and 300uM drugs from the library at early third instar stage,
then allow these larvae to grow and mature to the third instar stage
(120h of development), and then dissect the brain to study effects
on glioma growth and track survival on days 5-7 when other glioma
positive larvae die. Here, we present data from our screen on
promising drugs from this academic year’s testing focusing on
drugs H10 and H11. Once we identify potential glioma inhibitors in
the primary screens, we will validate them in secondary screens.
z
Future Directions
• We plan to continue the chemical screen using additional 
drugs from the Selleck Biochem Chemical library.
• We will begin to validate the potential glioma reducers to 
find the specificity and efficacy of these potential modifiers 
of glioma growth.
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Table 1: Drug Data Summary
Figure 1: Tumor Development 
Figure 3: Means for Comparison
A) Repo Control
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Conclusions
• Our data has provided multiple candidates for the 
secondary screen, especially E7, E11 and H10. 
• These drugs that are promising candidates for the 
second screen due to their potential suppression 
effects. 
• The method of comparison between larval brain 
images continues to provide sufficient data to either 
pursue or eliminate a drug from further 
experimentation. 
Figure 2: Drug Screen Process
Introduction
• This project is a chemical drug screen that has a goal to determine if
newly approved Tyrosine Kinase Inhibitors are capable of limiting
growth and progression of glioblastoma
• Two of the most frequent oncogenic pathways, Ras/MAPK and Pi3K,
were used to model human glioma in Drosophila
• Pten is a tumor suppressor and the down regulation of Pi3K was
deactivated through RNA interference
• Pten mutations are found in many patient biopsies of glioma
• RasV12 is the most frequent oncogenic mutation found in many human
tumors
• The expression of both Pteni; RasV12 in unison more accurately
models human glioblastoma in Drosophila
• In this chemical screen and this specific poster presentation, the
efficacy of chemical P1H10 and P1H11 are examined
Figure 4: P1H10 and P1H11
P1H10
Potential 
Suppression 
P1H11
No Effect 
Pteni; RasV12 X Repo; GFP Repo; GFP Control
Repo; GFP ControlPten
i; RasV12 X Repo; GFP
1. Pteni and Repo Stocks are prepared 
2. Female virgins are collected from the Pteni;RasV12 stock
3. Collected virgins are added to Repo males (2:1 ratio)
4. After Day 3, non-TM6B larvae are collected
5. The collected larvae are added to the drug vials
6. On Days 5 and 6, larvae are dissected, mounted and    
imaged 
7. Day 7 pupated larvae are collected and imaged
8. Data is recorded and analyzed 
P1E7 300um Day 5 Suppressed
P1E9
P1E11
P1H10
P1H11
10um
10um
300um
300um
Day 5
Day 5
Day 5
Day 5
No Effect
Suppressed
Suppressed
No Effect
Drug Concentration Dissection Results
